My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 454

    1.

    Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.

    Salpeter SR, Sanders GD, Salpeter EE, Owens DK.

    Ann Intern Med. 1997 Dec 15;127(12):1051-61.PMID: 9412307 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.

    Rose DN.

    Ann Intern Med. 1998 Nov 15;129(10):779-86.PMID: 9841583 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis.

    Rose DN, Schechter CB, Fahs MC, Silver AL.

    Am J Prev Med. 1988 Mar-Apr;4(2):102-9.PMID: 3134928 [PubMed - indexed for MEDLINE]Related articles

    4.

    Cost-effectiveness of isoniazid chemoprevention in close contacts.

    Diel R, Nienhaus A, Schaberg T.

    Eur Respir J. 2005 Sep;26(3):465-73.PMID: 16135730 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors.

    Rose DN, Schechter CB, Silver AL.

    JAMA. 1986 Nov 21;256(19):2709-13.PMID: 3773178 [PubMed - indexed for MEDLINE]Related articles

    6.

    Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis.

    Salpeter SR, Salpeter EE.

    Infect Control Hosp Epidemiol. 2004 Dec;25(12):1056-61.PMID: 15636292 [PubMed - indexed for MEDLINE]Related articles

    7.

    Isoniazid preventive therapy in areas of high isoniazid resistance.

    Sterling TR, Brehm WT, Frieden TR.

    Arch Intern Med. 1995 Aug 7-21;155(15):1622-8.PMID: 7618985 [PubMed - indexed for MEDLINE]Related articles

    8.

    Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective.

    Bell JC, Rose DN, Sacks HS.

    AIDS. 1999 Aug 20;13(12):1549-56.PMID: 10465080 [PubMed - indexed for MEDLINE]Related articles

    9.

    Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors.

    Colice GL.

    Arch Intern Med. 1990 Dec;150(12):2517-22.PMID: 2244768 [PubMed - indexed for MEDLINE]Related articles

    10.

    The cost-effectiveness of preventing tuberculosis in physicians using tuberculin skin testing or a hypothetical vaccine.

    Nettleman MD, Geerdes H, Roy MC.

    Arch Intern Med. 1997 May 26;157(10):1121-7.PMID: 9164378 [PubMed - indexed for MEDLINE]Related articles

    11.

    Tuberculin screening: cost-effectiveness analysis of various testing schedules.

    Schechter CB, Rose DN, Fahs MC, Silver AL.

    Am J Prev Med. 1990 May-Jun;6(3):167-75.PMID: 2118787 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.

    Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS.

    AIDS. 1999 Oct 22;13(15):2069-74.PMID: 10546859 [PubMed - indexed for MEDLINE]Related articles

    13.

    Exposure to tuberculosis among newborns in a nursery: decision analysis for initiation of prophylaxis.

    Berkowitz FE, Severens JL, Blumberg HM.

    Infect Control Hosp Epidemiol. 2006 Jun;27(6):604-11. Epub 2006 May 31.PMID: 16755481 [PubMed - indexed for MEDLINE]Related articles

    14.

    [Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings]

    Yoshiyama T.

    Kekkaku. 2000 Nov;75(11):629-41. Japanese. PMID: 11140086 [PubMed - indexed for MEDLINE]Related articles

    15.

    Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.

    Gourevitch MN, Alcabes P, Wasserman WC, Arno PS.

    Int J Tuberc Lung Dis. 1998 Jul;2(7):531-40.PMID: 9661818 [PubMed - indexed for MEDLINE]Related articles

    16.

    Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany.

    Diel R, Nienhaus A, Loddenkemper R.

    Chest. 2007 May;131(5):1424-34.PMID: 17494792 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.

    Montgomery AA, Fahey T, Ben-Shlomo Y, Harding J.

    J Hypertens. 2003 Sep;21(9):1753-9.PMID: 12923409 [PubMed - indexed for MEDLINE]Related articles

    18.

    [Tuberculosis in Iceland. 1976]

    Sigurdsson S.

    Laeknabladid. 2005 Jan;91(1):69-102. Icelandic. PMID: 16155306 [PubMed - indexed for MEDLINE]Related articles

    19.

    Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.

    Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG.

    Ann Intern Med. 2003 Jun 17;138(12):960-8.PMID: 12809452 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.

    Holland DP, Sanders GD, Hamilton CD, Stout JE.

    Am J Respir Crit Care Med. 2009 Jun 1;179(11):1055-60. Epub 2009 Mar 19.PMID: 19299495 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity